Third Harmonic Bio, Inc. THRD 深 沪
已收盘 07-30 16:00:00 美东时间
5.38
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 5.38
- 总市值 24.28万
- 52周最高 16.02
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.18
- 委 比 0.00%
- 总股本 4.51万
- 历史最高 24.595
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.18
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences reported Q2 2026 financial results and business updates, highlighting the full enrollment of its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, exceeding targets and on track for 2H 2027 topline data. The company refocused its strategic plan on ocular oncology, deprioritizing the NMIBC program while maintaining data collection. Organizational restructuring and leadership appointments were announced to align resour...
08-11 11:00
AnaptysBio appoints Christopher Murphy as CFO
AnaptysBio (ANAB) on Monday announced the appointment of Christopher Murphy as Chief Financial Officer. Murphy, previously, served as CFO and CBO of Third Harmonic Bio. Before Third Harmonic, he serve...
05-11 21:25
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio appoints Christopher Murphy as CFO and Owen Hughes to its Board, enhancing expertise in finance, business development, and royalty management. Murphy brings extensive experience in corporate strategy and investment banking, while Hughes has over two decades of leadership in royalty management and corporate development. AnaptysBio focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to pr...
05-11 13:15
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma appoints Shao-Lee Lin, M.D., Ph.D., as CEO and President. Dr. Lin brings over 25 years of biopharmaceutical leadership experience, including successful IPOs and regulatory approvals. She will lead the advancement of CUE-401, a novel therapeutic for autoimmune diseases, and expand the clinical pipeline. Cue Biopharma focuses on developing innovative therapies targeting T cells to address autoimmune and inflammatory conditions.
04-30 20:05
Third Harmonic Bio to Delist from Nasdaq
Third Harmonic Bio, Inc. ( ($THRD) ) has issued an announcement. On July 31, 20...
2025-08-01 02:57
Third Harmonic Bio Approves Liquidation and Dissolution Plan
The latest update is out from Third Harmonic Bio, Inc. ( ($THRD) ). Third Harmo...
2025-06-12 20:29
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Third Harmonic Bio, Inc. announced that its stockholders overwhelmingly approved the Plan of Liquidation and Dissolution at the June 5, 2025 Annual Meeting. The initial distribution to stockholders is expected to be between $5.30 and $5.35 per share in the third quarter of 2025. Additionally, the company shared updated Phase 1 clinical data for THB335, showing an 85% reduction in serum tryptase with a favorable safety profile. The company has als...
2025-06-12 12:00
Third Harmonic Bio Q1 EPS $(0.35) Misses $(0.29) Estimate
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 75 percent decrease over losses of $(0.20) per share from
2025-05-09 05:53
